Heart Failure

Dr Stefan Anker: Patients With HFpEF Deserve a New Treatment

September 21st 2021, 7:00pm


With empagliflozin, we now have evidence that another treatment for patients with heart failure with preserved ejection fraction (HFpEF) is possible, said Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany, and principal investigator of the EMPEROR-Preserved study.

Diagnosis Patterns and Stress Testing Trends After Implementing High-Sensitivity Troponin Assay

September 17th 2021, 1:00pm


This study found that switching from a conventional troponin assay to a high-sensitivity troponin assay resulted in changes to diagnosis patterns and stress testing trends.

Mom’s Meals Launches Pilot Program for California Health Plan Members With Heart Failure

September 16th 2021, 6:49pm


The 6-month program provides nutrition education, healthy food and recipes, and home visits.

Lower Rehospitalization, Mortality Seen From Sacubitril/Valsartan Use for HFrEF

September 15th 2021, 12:00pm


Entresto (sacubitril/valsartan) was first approved for use in heart failure with reduced ejection fraction (HFrEF) in 2015.

Panel Outlines Updates on HF Treatment Developments, Recommendations for Guidelines

September 13th 2021, 4:30pm


In a panel at the 5th annual Heart in Diabetes Conference, John McMurray, MD, and Javed Butler, MD, highlighted recent pharmacological developments in heart failure (HF) and offered insights on overlooked areas in the field.

ESC Congress 2021: Solutions for Gender-Based Gap in Cardiovascular Disease Diagnosis

September 10th 2021, 4:24pm


The Lancet commission aimed to connect stakeholders, raise global awareness of these inequities and disparities, and encourage future research.

Dr Javed Butler Discusses the Possibility of HFpEF Combination Treatment

September 7th 2021, 6:30pm


Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), noted Javed Butler, MD, MPH, MBA, of the University of Mississippi.

Dr Rudolf de Boer on SGLT2 Inhibitor Success Across Disease States

September 4th 2021, 12:00pm


Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to both lower blood pressure and promote weight loss, and they act rather subtly, stated Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.

STEP Trial Findings Build on SPRINT Results, With a Twist

September 2nd 2021, 10:15pm


STEP findings build on those from the SPRINT trial, seemingly confirming that intensive treatment for hypertension can reduce the risk of serious adverse cardiovascular (CV) outcomes. However, there was no significant benefit toward risk for all-cause and CV-related mortality.

Better Screening Efforts Needed for Patients With T2MI, Heart Failure

August 26th 2021, 9:00pm


Although there is an established link between type 2 myocardial infarction (T2MI) and elevated rates of cardiovascular events, less is known about the connection between T2MI and heart failure—which this new study investigated.